In one pivotal trial (EMILIA), T-DM1 demonstrated robust clinical activity in patients with trastuzumab-refractory HER2-positive breast cancer with a 43.6% objective response rate and median progression-free survival of 9.6 months 3. This evidence concerns the gene ERBB2 and breast carcinoma.